A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa

NCT00447980 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

Retinitis Pigmentosa

Interventions

DRUG: NT-501
DRUG: NT-501

Sponsor

Neurotech Pharmaceuticals